ImmunityBio, Inc. (IBRX)

3,7200 -0,0600 (-1,59%) Al cierre: 04:00PM EST

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
858 633 0300
https://immunitybio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 670

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board, Global Chief Scientific & Medical Officer	629,19k	N/A	1953
Mr. Richard Gerald Adcock	President, CEO & Director	849,45k	N/A	1969
Mr. David C. Sachs	CFO, Principal Financial Officer & Principal Accounting Officer	533,33k	N/A	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/A	N/A	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	N/A	N/A	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	N/A	N/A	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	N/A	N/A	N/A
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Hans Georg Klingemann M.D., Ph.D.	Chief Science Officer of Cellular	N/A	N/A	1950

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de ImmunityBio, Inc., a día 1 de diciembre de 2023, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 6; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.